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Abstract
The role of chorioamnionitis (CA) in the development of retinopathy of prematurity (ROP) is
difficult to establish, because CA-exposed and CA-unexposed infants frequently present dif-
ferent baseline characteristics. We performed an updated systematic review and meta-anal-
ysis of studies reporting on the association between CA and ROP. We searched PubMed
and EMBASE for relevant articles. Studies were included if they examined preterm or very
low birth weight (VLBW, <1500g) infants and reported primary data that could be used to
measure the association between exposure to CA and the presence of ROP. Of 748 poten-
tially relevant studies, 50 studies met the inclusion criteria (38,986 infants, 9,258 CA cases).
Meta-analysis showed a significant positive association between CA and any stage ROP
(odds ratio [OR] 1.39, 95% confidence interval [CI] 1.11 to 1.74). CA was also associated
with severe (stage�3) ROP (OR 1.63, 95% CI 1.41 to 1.89). Exposure to funisitis was asso-
ciated with a higher risk of ROP than exposure to CA in the absence of funisitis. Additional
meta-analyses showed that infants exposed to CA had lower gestational age (GA) and
lower birth weight (BW). Meta-regression showed that lower GA and BW in the CA-exposed
group was significantly associated with a higher risk of ROP. Meta-analyses of studies with
data adjusted for confounders could not find a significant association between CA and ROP.
In conclusion, our study confirms that CA is a risk factor for developing ROP. However, part
of the effects of CA on the pathogenesis of ROP may be mediated by the role of CA as an
etiological factor for very preterm birth.
Introduction
Chorioamnionitis (CA) is a major risk factor for preterm birth, especially at earlier gestational
age (GA), and a major contributor to prematurity-associated morbidity and mortality [1–6].
The pathogenetic role of CA in the development of adverse outcomes of prematurity, such as
PLOS ONE | https://doi.org/10.1371/journal.pone.0205838 October 17, 2018 1 / 20
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Villamor-Martinez E, Cavallaro G, Raffaeli
G, Mohammed Rahim OMM, Gulden S, Ghazi
AMT, et al. (2018) Chorioamnionitis as a risk factor
for retinopathy of prematurity: An updated
systematic review and meta-analysis. PLoS ONE
13(10): e0205838. https://doi.org/10.1371/journal.
pone.0205838
Editor: Olivier Baud, Hopital Robert Debre, FRANCE
Received: March 28, 2018
Accepted: October 2, 2018
Published: October 17, 2018
Copyright: © 2018 Villamor-Martinez et al. This is
an open access article distributed under the terms
of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.
bronchopulmonary dysplasia (BPD) [6–8], necrotizing enterocolitis (NEC) [9], patent ductus
arteriosus (PDA) [10, 11], neonatal brain injury [12], or cerebral palsy [13], has been addressed
in a number of cohort and case-control studies, which have been summarized in systematic
reviews. Nevertheless, it is still controversial whether the effects of CA on neonatal mortality
and morbidity are related to infection/inflammation or to the role of CA as an etiological fac-
tor for very preterm birth [1–6].
Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the developing retina
and a leading cause of childhood blindness around the world [14–20]. Prematurity and postna-
tal oxygen therapy have consistently been associated with ROP [14–21]. However, ROP is a
multifactorial disease, and multiple other modifiable clinical factors have been associated with
an increased risk of ROP. These include, among others, hypoxia, hypercapnia, hyperglycemia,
exposure to blood transfusions, or poor postnatal weight gain [14–19, 22–27]. In addition,
recent experimental and clinical data support the hypothesis that multiple hits of antenatal and
postnatal infection/inflammation are involved in ROP etiology and progression [16, 28].
The role of CA as a potential pathogenic factor for ROP has already been the subject of a
systematic review and meta-analysis [29]. Mitra et al. [29] included 27 studies (10,590 preterm
infants) in their review. They found, in unadjusted analyses, that CA was significantly associ-
ated with ROP (any stage, summary risk ratio 1.33, 95% confidence interval [CI] 1.14 to 1.55),
but that CA was not significantly associated with severe ROP (stage�3, summary risk ratio
1.27, 95% CI 0.99 to 1.63) [29]. They also carried out subgroup analysis of studies which did
not show a significant difference in GA between the CA-exposed and CA-unexposed groups.
In this analysis they could not find a significant association between CA and ROP (risk ratio
0.98, 95% CI 0.77 to 1.26). They concluded that CA could not definitively be considered a risk
factor for ROP, and that further studies that adjust for potential confounding factors were
required [29].
After the publication of the meta-analysis by Mitra et al. [29], more studies assessing the
relationship between CA and ROP have been published. Some of these studies are of high
methodological quality and included large infant populations. Therefore, in the present study,
we aimed to update the meta-analysis of Mitra et al. [29]. We used an extensive search strategy,
which included not only studies describing ROP as an outcome after exposure to CA, but also
studies that assessed CA as potential risk factor for ROP. In addition, we analyzed the magni-
tude of the differences in potential confounders, such as GA, birth weight (BW), rate of sepsis,
or exposure to antenatal corticosteroids between the infants of the CA and the control group.
Finally, we performed a meta-regression in order to investigate the effect of confounders on
the association between CA and ROP.
Methods
The methodology of this study was based on an earlier meta-analysis on the association of CA
and PDA [11], and on another meta-analysis on probiotics and ROP [30]. The study was con-
ducted according to the Guidelines for Meta-Analyses and Systematic Reviews of Observa-
tional Studies (MOOSE) [31] and the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) [32]. The study is reported according to the PRISMA checklist
(S1 File).
Sources and search strategy
A comprehensive literature search was undertaken using the PubMed/MEDLINE and
EMBASE databases from their inception to July 1, 2017. The search terms involved various
combinations of the following keywords: “chorioamnionitis”, “intrauterine infection”
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“intrauterine inflammation”, “antenatal infection” “antenatal inflammation”, “retinopathy of
prematurity”, “risk factors”, “outcome”, “cohort”, and “case-control”. The search strategy for
PubMed/MEDLINE is described in detail in S1 Table. No language limit was applied. Addi-
tional strategies to identify studies included manual review of reference lists from key articles
that fulfilled our eligibility criteria and other systematic reviews on CA, use of “related articles”
feature in PubMed, and use of the “cited by” tool in Web of Sciences and Google scholar.
Study selection
Studies were included if they examined preterm or very low birth weight (VLBW, <1500g)
infants and reported primary data that could be used to measure the association between expo-
sure to CA and the presence of ROP. Therefore, we selected studies describing ROP as out-
come after exposure to CA, and studies that assessed CA as a potential risk factor for ROP.
Studies were considered for inclusion if they were cohort studies, case control studies or ran-
domized controlled trials with a control arm which met the inclusion criteria. To identify rele-
vant studies, two reviewers (E.V., G.C.) independently screened the results of the searches and
applied inclusion criteria using a structured form. Discrepancies were resolved through discus-
sion or consultation with a third reviewer (P.D.).
Data extraction
A team of three investigators (G.C., S.G., G.R.) extracted data from relevant studies using a
predetermined data extraction form, and a second team of four investigators (E.V.-M., A.G.,
O.R., P.D.) checked data extraction for accuracy and completeness. Discrepancies were
resolved by consulting the primary report. Data extracted from each study included citation
information, language of publication, location where research was conducted, time period of
the study, study objectives, study design, definitions of CA and ROP, inclusion/exclusion crite-
ria, patient characteristics, and results (including raw numbers, summary statistics and
adjusted analyses on CA and ROP where available). Severe ROP was defined as ROP stage� 3.
Quality assessment
Methodological quality was assessed using the Newcastle-Ottawa Scale for cohort or case-con-
trol studies [33]. This scale uses a rating system (range: 0–9 points) that scores three aspects of
a study: selection (0–4 points), comparability (0–2 points) and exposure/outcome (0–3 points).
Studies were evaluated as though the association between CA and ROP was the primary out-
come. Two reviewers (E.V.-M. and E.V.) independently assessed the methodological quality of
each study. Discrepancies were resolved through discussion.
Statistical analysis
Studies were combined and analyzed using COMPREHENSIVE META-ANALYSIS V3.0 software (Biostat
Inc., Englewood, NJ, USA). For dichotomous outcomes, the odds ratio (OR) with 95% confi-
dence interval (CI) was calculated from the data provided in the studies. ORs adjusted for
potential confounders were extracted from the studies reporting these data. For continuous
outcomes, the mean difference (MD) with 95% CI was calculated. When studies reported con-
tinuous variables as median and range or interquartile range, we estimated the mean and stan-
dard deviation using the method of Wan et al. [34].
Due to anticipated heterogeneity, summary statistics were calculated with a random-effects
model. This model accounts for variability between studies as well as within studies. Subgroup
analyses were conducted according to the mixed-effects model [35]. In this model, a random-
Chorioamnionitis and retinopathy of prematurity
PLOS ONE | https://doi.org/10.1371/journal.pone.0205838 October 17, 2018 3 / 20
effects model is used to combine studies within each subgroup, and a fixed-effect model is
used to combine subgroups and yield the overall effect. The study-to-study variance (tau-
squared) is not assumed to be the same for all subgroups. This value is computed within sub-
groups and not pooled across subgroups. Statistical heterogeneity was assessed by Cochran’s Q
statistic and by the I2 statistic, which is derived from Q and describes the proportion of total
variation that is due to heterogeneity beyond chance [36]. We used the Egger’s regression test
[37] and funnel plots to assess publication bias. To explore differences between studies that
might be expected to influence the effect size, we performed univariate random-effects meta-
regression (method of moments) [38]. The potential sources of variability defined a priori
were: CA type (clinical or histological), differences in GA and BW between the infants with
and without CA, use of antenatal corticosteroids, mode of delivery, rate of small for gestational
age (SGA), rate of premature rupture of membranes (PROM), rate of preeclampsia, rate of
early-onset sepsis (EOS), rate of late-onset sepsis (LOS), and mortality. Additional sensitivity
analyses were performed excluding studies that included infants with GA>32 weeks. A proba-
bility value of less than 0.05 (0.10 for heterogeneity) was considered statistically significant.
Results
Description of studies
Of 748 potentially relevant studies, 50 met the inclusion criteria [12, 39–87]. The PRISMA
flow diagram of the search process is shown in Fig 1. The included studies evaluated 38,956
infants, and included 9258 CA cases, 3251 cases of all stages ROP, and 2720 cases of severe
ROP. The included studies and their characteristics are summarized in S2 Table. None of the
studies were designed to primarily examine the association between CA and ROP. In 35 stud-
ies, the aim was to examine the outcomes, including ROP, of preterm infants with and without
maternal CA. Fifteen studies examined the risk factors for ROP, including maternal CA. Nine-
teen studies used a clinical definition of CA and 26 studies used a histological definition. In
two studies [57, 87], ROP was associated with clinical CA and with histological CA separately.
In two studies [55, 65], infants were considered to have CA if they had both clinical and histo-
logical CA. In the study of Gray et al. [47] infants were assigned to the CA group if they had
clinical or histological CA. Finally, 43 of the 50 studies included infants who were at least <32
weeks GA or had a BW <1500g. One study included infants of<33 weeks [68], five studies
included infants up to GA 34 weeks [40, 52, 54, 55, 63], and one study included infants of GA
<37 weeks [70].
Quality assessment
The quality of each study according to the Newcastle-Ottawa Scale is summarized in S2 Table.
Most (k = 40) studies received a quality score of 6 or 7 points. Studies were downgraded in
quality most frequently for not adjusting the risk of ROP for confounders (k = 42), for not
defining ROP clearly (k = 24), and for not defining CA clearly (k = 16).
Analysis based on unadjusted data
As shown in Fig 2, meta-analysis showed a significant positive association between all types
CA and any stage ROP. The association remained significant for histological, but not for clini-
cal CA. Excluding studies [40, 54, 63, 70] that included older premature infants (GA 32–37
weeks) did not significantly affect the association between CA and any stage ROP (OR 1.34,
95% CI 1.05 to 1.71). Moreover, as shown in Fig 3, meta-analysis showed a significant positive
association between all types CA and severe ROP. The association remained significant for
Chorioamnionitis and retinopathy of prematurity
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both histological and clinical CA. The study of Soraisham et al. [68] included older infants (up
to 33 weeks GA) and its exclusion did not significantly affect the association between CA and
severe ROP (OR 1.62, 95% CI 1.39 to 1.89). Three studies reported on ROP stage�1, and
meta-analysis demonstrated a significant positive association with CA (S1 Fig). This associa-
tion became non-significant when a study which included infants up to 34 weeks GA [52] was
removed from the analysis (OR 1.89, CI 1.06 to 3.29). Finally, as shown in Fig 4, ROP stage
1–2 was not significantly associated with all types CA, clinical CA, or histological CA. Neither
visual inspection of the funnel plot nor the regression test of Egger revealed evidence of publi-
cation bias in the analyses of all stages ROP, severe ROP, or stage 1–2 ROP (S2 Fig). There
were too few studies (k = 3) reporting on stages�1 ROP to test for publication bias.
To explore the possible differences in baseline characteristics between the groups exposed
and non-exposed to CA, we performed several additional meta-analyses. As summarized in
Tables 1 and 2, infants exposed to CA showed significantly lower GA and BW, significantly
Fig 1. PRISMA flow diagram of search process. CA: Chorioamnionitis; ROP: retinopathy of prematurity.
https://doi.org/10.1371/journal.pone.0205838.g001
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lower rates of birth by cesarean delivery, significantly lower rates of SGA, significantly lower
rates of preeclampsia, and significantly lower rates of maternal diabetes. Moreover, infants
exposed to CA showed significantly higher rates of exposure to antenatal corticosteroids, sig-
nificantly higher rates of PROM, significantly higher rates of EOS, significantly higher rates of
LOS, and significantly higher mortality.
To analyze the possible influence of the GA and BW on the unadjusted association between
CA and ROP, we performed meta-regression analyses. These analyses showed that the
Fig 2. Meta-analysis of chorioamnionitis and risk of any stage ROP. CA: chorioamnionitis; ROP: retinopathy of prematurity; (c):
clinical chorioamnionitis; (h): histological chorioamnionitis.
https://doi.org/10.1371/journal.pone.0205838.g002
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differences in GA or BW between the CA exposed and non-exposed groups were significantly
correlated with the risk of ROP in the CA-exposed group (Table 3). Specifically, we found a
significant correlation between an increasing mean difference in GA and a higher CA-associ-
ated risk of all stages ROP (Fig 5), stages 1–2 ROP (S3 Fig) and severe ROP (Fig 6). Moreover,
we found a significant correlation between an increasing mean difference in BW and a higher
CA-associated risk of all stages ROP (S4 Fig), and stages 1–2 ROP (S5 Fig). In contrast, meta-
regression could not demonstrate a significant correlation between an increasing MD in BW
and a higher CA-associated risk of severe ROP (Table 3).
To eliminate the effect of prematurity as a confounding factor, we carried out a meta-analy-
sis of studies where the mean difference in GA was non-significant (p> 0.05). Ten studies met
Fig 3. Meta-analysis of chorioamnionitis and risk of severe ROP (stage�3). CA: chorioamnionitis; ROP: retinopathy of
prematurity; (c): clinical chorioamnionitis; (h): histological chorioamnionitis.
https://doi.org/10.1371/journal.pone.0205838.g003
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this criterion. As shown in S6 Fig, we could not find a significant association between any type
CA and all stages ROP, or any type CA and severe ROP.
In addition, we carried out meta-regression analyses to examine the effect of other covari-
ates on the risk of ROP (S3 Table). We examined the effect of the covariates we predefined on
Fig 4. Meta-analysis of chorioamnionitis and risk of stage 1–2 ROP. CA: chorioamnionitis; ROP: retinopathy of prematurity; (c):
clinical chorioamnionitis; (h): histological chorioamnionitis.
https://doi.org/10.1371/journal.pone.0205838.g004
Table 1. Meta-analysis of chorioamnionitis and continuous variables.
Meta-analysis CA type k Mean difference 95% CI Z p Heterogeneity
Q p I2 (%)
Gestational age (weeks) Clinical 7 -0.94 -1.44 to -0.43 -3.60 <0.001 158.7 <0.001 96.2
Histological 9 -1.42 -1.85 to -0.99 -6.53 <0.001 118.6 <0.001 93.3
Any type 18 -1.15 -1.44 to -0.85 -7.61 <0.001 312.5 <0.001 94.6
Birth weight (g) Clinical 8 -19 -72 to 34 -0.71 0.480 127.1 <0.001 94.5
Histological 19 -49 -86 to -11 2.57 0.010 155.5 <0.001 88.4
Any type 29 -34 -62 to -6 -2.38 0.017 294.1 <0.001 90.5
Maternal age (years) Any type 5 -0.31 -1.61 to 0.99 -0.47 0.639 37.2 <0.001 89.3
CA: chorioamnionitis; k: number of included studies. Mean differences represent the mean of the CA-exposed group minus the mean of the CA-unexposed group.
Statistically significant mean differences are marked in bold.
https://doi.org/10.1371/journal.pone.0205838.t001
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Table 2. Meta-analysis of chorioamnionitis and dichotomous variables.
Meta-analysis CA type k OR 95% CI Z p Heterogeneity
Q p I2 (%)
Antenatal Corticosteroids (any dosage) Clinical 6 1.19 0.79 to 1.79 0.84 0.402 73.5 <0.001 93.2
Histological 18 1.28 1.00 to 1.64 1.96 0.050 85.3 <0.001 80.1
Any type 25 1.25 1.03 to 1.52 2.21 0.027 162.0 <0.001 85.2
Cesarean section Clinical 7 0.33 0.19 to 0.57 -3.93 <0.001 278.3 <0.001 97.8
Histological 14 0.34 0.23 to 0.49 -5.52 <0.001 86.8 <0.001 85.0
Any type 22 0.34 0.26 to 0.45 -7.33 <0.001 368.3 <0.001 94.3
Maternal diabetes Any type 2 0.71 0.53 to 0.95 -2.29 0.022 0.1 0.775 0.0
Preeclampsia Histological 5 0.20 0.16 to 0.25 -13.20 <0.001 1.4 0.844 0.0
PROM Clinical 2 5.99 2.52 to 14.26 4.05 <0.001 5.0 0.025 80.0
Histological 9 3.37 2.21 to 5.16 5.61 <0.001 87.6 <0.001 90.9
Any type 11 3.78 2.61 to 5.47 7.04 <0.001 99.0 <0.001 89.9
Small for gestational age Clinical 2 0.48 0.16 to 1.49 -1.47 0.204 0.01 0.925 0.0
Histological 9 0.32 0.18 to 0.56 -4.04 <0.001 90.0 <0.001 91.1
Any type 11 0.35 0.22 to 0.55 -4.44 <0.001 90.1 <0.001 88.9
Early onset sepsis Clinical 7 4.51 3.29 to 6.19 9.36 <0.001 6.1 0.409 2.1
Histological 10 3.68 2.53 to 5.36 6.81 <0.001 21.2 0.012 57.6
Any type 17 4.15 3.26 to 5.28 11.55 <0.001 27.5 0.036 41.9
Late onset sepsis Clinical 4 1.30 0.86 to 1.98 1.23 0.219 12.4 0.006 75.9
Histological 11 1.40 1.05 to 1.86 2.31 0.021 75.5 <0.001 86.8
Any type 16 1.35 1.09 to 1.67 2.78 0.005 89.1 <0.001 83.2
Mortality Clinical 7 1.66 1.26 to 2.18 3.65 <0.001 17.1 0.009 64.9
Histological 13 1.47 1.15 to 1.87 3.17 0.002 37.3 <0.001 67.9
Any type 21 1.52 1.25 to 1.85 4.15 <0.001 81.1 <0.001 75.3
CA: chorioamnionitis; k: number of included studies; OR: odds ratio; PROM: premature rupture of membranes; SGA: small for gestational age. An OR higher than 1
indicates that CA is a risk factor for the outcome, an OR below one indicates that CA is a protective factor for the outcome. Statistically significant odds ratios are
marked in bold.
https://doi.org/10.1371/journal.pone.0205838.t002
Table 3. Meta-regression of difference in gestational age and difference in birth weight and risk of ROP.
ROP stage Meta-regression k Coefficient 95% CI Z p
All stages ROP Difference in mean GA
(per week)
19 -0.52 -0.99 to -0.06 -2.21 0.027
Difference in mean BW
(per 100 g)
19 -0.34 -0.68 to -0.01 -2.04 0.042
Stages 1–2 ROP Difference in mean GA
(per week)
7 -0.58 -0.96 to -0.21 -3.06 0.002
Difference in mean BW
(per 100 g)
7 -0.36 -0.57 to -0.15 -3.39 0.001
Severe ROP (stage �3) Difference in mean GA
(per week)
17 -0.49 -0.66 to -0.31 -5.30 <0.001
Difference in mean BW
(per 100 g)
16 -0.03 -0.22 to 0.16 -0.29 0.774
ROP: retinopathy of prematurity; GA: gestational age; BW: birth weight; k: number of included studies; CI: confidence interval
https://doi.org/10.1371/journal.pone.0205838.t003
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the risk of ROP in the CA-exposed group. We found that an increased risk of EOS in the CA-
group significantly correlated with an increased risk of all grades ROP. Moreover, an increased
risk of SGA in the CA-group significantly correlated with an increased risk of all grades ROP.
Finally, an increased risk of mortality in the CA-group correlated with an increased risk of
severe ROP. Other meta-regression analyses of confounders did not show significant
associations.
We performed additional analyses aimed at evaluating the role of the presence of fetal
inflammatory response (i.e., funisitis) on the development of ROP (S7 Fig). Two studies
reported on all grades ROP in infants with histological CA, with or without funisitis. Meta-anal-
ysis showed a significant increase in risk of all stages ROP in infants who had funisitis, com-
pared to infants who had CA without funisitis. Two studies reported on severe ROP in infants
with funisitis. Meta-analysis showed a significant increase in severe ROP risk in funisitis-posi-
tive infants, compared to infants who were only CA-positive (S7 Fig). Finally, when considering
any stage ROP and severe ROP together, we observed an increase in risk of ROP in the funisi-
tis-exposed group (S7 Fig). However, additional meta-analysis showed the groups also differed
in degree of prematurity. Funisitis-positive infants had significantly lower GA (MD -1.30
weeks, 95% CI -1.37 to -1.23, p< 0.0001) than the CA-exposed infants without funisitis.
Analysis based on adjusted data
Eight studies reported adjusted data on CA-exposure and ROP risk. As described in S4 and S5
Tables, studies adjusted for different covariates. Meta-analysis of unadjusted data in these
Fig 5. Meta-regression plot of association between chorioamnionitis and all stages ROP controlling for difference in GA
between exposed and non-exposed groups. CA: chorioamnionitis; ROP: retinopathy of prematurity; GA: gestational age.
https://doi.org/10.1371/journal.pone.0205838.g005
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studies showed that CA-infants were at a significant risk of all stages ROP (OR 1.73, 95% CI
1.33 to 2.25, S4 Table). Similarly, unadjusted data from these studies showed a significant risk
of severe ROP in the CA-group (OR 2.00, 95% CI 1.46 to 2.74, S5 Table). We compared the
results of the unadjusted analyses to the adjusted ORs reported in these 8 studies. When using
adjusted data, meta-analysis could no longer find a significant association between CA (histo-
logical, clinical and any type) and ROP (all stages ROP: OR 1.29, 95% CI 0.87 to 1.91, S4 Table;
severe ROP: OR 1.17, 95% CI 0.88 to 1.56, S5 Table).
Discussion
Our updated meta-analysis included a greater pool of studies (50 vs. 27) and a larger number
of infants (38,956 vs. 10,590) than the meta-analysis of Mitra et al. [29], but further confirmed
their results. We observed a significant positive association between any CA and all stages of
ROP. This association was significant for histological but not for clinical CA. In contrast, both
clinical and histological CA were associated with severe ROP. Exposure to funisitis was associ-
ated with a higher risk of ROP than exposure to CA in the absence of funisitis. Additional
meta-analyses showed that infants exposed to CA had significantly lower GA and lower BW
than the infants not exposed to CA. Meta-regression showed that these differences in GA and
BW were significantly correlated with a higher risk of ROP in the CA-exposed group. Meta-
regression also showed that higher rates of EOS, SGA, and mortality in the CA-exposed group
correlated significantly with a higher risk of ROP. Meta-analyses of studies with adjusted data
Fig 6. Meta-regression plot of association between chorioamnionitis and severe ROP (stage�3) controlling for difference in
GA between exposed and non-exposed groups. CA: chorioamnionitis; ROP: retinopathy of prematurity; GA: gestational age.
https://doi.org/10.1371/journal.pone.0205838.g006
Chorioamnionitis and retinopathy of prematurity
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could not find an association between CA and ROP. In summary, our study confirms that CA
is a risk factor for developing ROP. However, part of the effects of CA on the pathogenesis of
ROP may be mediated by the role of CA as an etiological factor for very preterm birth.
Assessment of CA as a risk factor for adverse outcomes in (very) preterm infants is ham-
pered by the lack of a ‘normal’ control group. Two broad pathological conditions have been
identified to lead to very preterm birth: (i) infection/inflammation and (ii) placental dysfunc-
tion resulting from vascular malfunction [88, 89]. As discussed elsewhere [11, 90], in addition
to distinct pathophysiological pathways, baseline and clinical characteristics are different
between these two groups [88, 91]. Accordingly, our analyses showed that the infants exposed
to CA were born significantly earlier (~1.15 weeks), were lighter (~35 g), had a higher rate of
exposure to antenatal corticosteroids, had a lower rate of cesarean section, were less often
SGA, had a higher rate of PROM, had a higher rate of EOS and LOS, and had a higher mortal-
ity. Some of these differences may have had a direct or indirect influence on the development
of ROP.
We performed meta-regression analyses to evaluate the potential impact of confounders on
the risk of ROP. Meta-regression is a statistical technique which examines the relationship
between continuous or categorical moderators and the size of effects observed in the studies
[38, 92]. Thus, meta-regression allows for the exploration of more complex questions than tra-
ditional meta-analysis. The present meta-regression demonstrated that the studies with higher
differences in GA and BW between the CA-exposed and CA-unexposed group were also the
studies where infants with CA had a greater risk of ROP. Previous meta-regression analyses
found a similar correlation between the differences in GA and BW and the CA-associated risk
of BPD [8] and PDA [11].
Additionally, we observed that when the few studies that corrected for GA, BW, and other
confounding factors were pooled, they did not show a significant increase in the risk of ROP
(S4 and S5 Tables). This supports the idea that GA, BW and other confounders significantly
modify the association between CA and ROP. Previous meta-analyses on the relationship
between CA and BPD [8], or cerebral palsy [13], showed that the positive association observed
with unadjusted data was significantly reduced, or became non-significant, when adjusted
data were pooled. Moreover, in another meta-analysis, the significant positive association
between CA and PDA became a significant negative association when only adjusted data were
taken into consideration [11]. As mentioned in the introduction, in their meta-analysis on CA
and ROP, Mitra et al. [29] did not pool the studies with adjusted results but performed a sub-
group analysis of studies which did not show a significant difference in GA between the CA-
exposed and CA-unexposed group. In this subgroup of studies, CA was not significantly asso-
ciated with ROP. This finding is confirmed in the present meta-analysis, underlining the idea
that the effects of CA on ROP development are, at least in part, related to its ability to induce
(very) preterm birth.
That the fetal inflammatory response induced by CA might specifically influence the devel-
opment of the fetal retina is a biologically plausible hypothesis. It has been suggested that mul-
tiple hits of antenatal and postnatal infection/inflammation are involved in ROP etiology and
progression [16, 28, 93, 94]. Proinflammatory cytokines may exert a direct effect on retinal
angiogenesis or sensitize the developing retina to the effects of postnatal oxygen, or other
stressors. [16, 94]. After birth, the circulatory instability and fluctuation of oxygen saturation
following infection/inflammation may affect the retinal perfusion and lead to increased retinal
injury. Our meta-analysis shows that CA is not only a risk factor for ROP but also a risk factor
for EOS and LOS. Moreover, meta-regression showed a correlation between the effect size of
the CA-ROP association and the CA-EOS association. In addition, the meta-analysis of Been
et al. [9] demonstrated that CA was a risk factor for NEC, a complication of prematurity in
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which inflammation plays an important pathogenic role. Altogether, these data suggest that
CA-exposed infants are more prone to be exposed to postnatal infection/inflammation and
that this propensity makes these infants more vulnerable to ROP.
CA will not always lead to an inflammatory process extending to the fetal component [95].
Funisitis is considered the histologic counterpart of the fetal inflammatory response syndrome
[5, 95]. Our analysis showed that the presence of funisitis increased the risk of developing ROP
when compared with CA in the absence of funisitis (S8 Fig). These data support the role of the
fetal inflammatory response as etiopathogenic factor for ROP. Nevertheless, the number of
studies including data on funisitis was rather limited. In addition, infants with funisitis also
presented a significantly lower GA when compared with infants with CA without funisitis.
Therefore, as in the case of CA, the effects of funisitis on ROP may be related to mechanisms
that involve fetal inflammation but also to mechanisms that induce earlier birth.
A further point of interest is that, as assessed by Dammann et al. [77], risk factor patterns
for ROP occurrence and progression might differ. A large proportion of very preterm infants
will develop low-grade ROP, while in a small proportion it will progress to high-grade disease
[77]. Of note, our meta-analysis could not demonstrate that CA was a significant risk factor
for ROP stage 1–2 (Fig 4). Recent clinical data suggest that infection/inflammation mecha-
nisms are mainly related to the more advanced stages of ROP, particularly the so-termed
aggressive posterior ROP (APROP) [28, 93].
As mentioned above, the two main etiological groups for very preterm birth are infection/
inflammation and placental vascular dysfunction [88, 89]. Two recent meta-analyses have
studied the risk of ROP of conditions related to the vascular dysfunction group. Neither Chan
et al. [27] nor Zhu et al. [96] could demonstrate that maternal or gestational hypertensive dis-
orders affected the risk of developing ROP. However, they did not analyze the differences in
basal characteristics between the group of infants exposed and unexposed to maternal/gesta-
tional hypertensive disorders. We speculate that the exposed infants probably had a higher GA
than the ‘control’ infants and that this difference may have influenced the risk of ROP.
Limitations of the literature and our systematic review and meta-analysis deserve comment.
First, the published literature showed great heterogeneity in definition of CA, and in assessment
of confounders. Particularly, criteria for the use of the term clinical CA are highly variable, and
recent recommendations propose to restrict the term CA to pathologic diagnosis [97]. Second,
none of the included studies evaluated the association between CA and ROP as their main
objective. Third, adjusted data were available only from 8 of the 50 studies included in the
meta-analysis. In addition, we had to rely on the adjusted analyses as presented in the published
reports and the variables for which they adjusted, which were not consistent across studies.
Finally, meta-regression uses summary data at the study level, meaning we cannot comment on
data of individual infants within a study and there is a risk of ecological bias [98]. On the other
hand, the main strengths of the present study are the large number of included studies and the
use of rigorous methods, including an extensive and comprehensive search; duplicate screen-
ing, inclusion, and data extraction to reduce bias; meta-analysis of baseline and secondary char-
acteristics; and the use of meta-regression to control for potential confounders.
Conclusions
ROP is a multifactorial disease that occurs in the youngest and sickest preterm infants [14–20,
99]. Our data show that CA, particularly when accompanied by funisitis, is a risk factor for
ROP, but also a risk factor for being a younger and sicker preterm infant. Clinical and experi-
mental evidence suggests that low GA, oxygen stress, as well as ante- and postnatal infection/
inflammation are not only independent risk factors for ROP but also interact beyond additive
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and even multiplicative patterns [16, 22, 100]. Future preventive and therapeutic strategies
aimed to reduce ROP, as well as other complications of prematurity, should be tailored, as
much as possible, to the particular pathogenic pathway leading to very preterm birth.
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